Drs. Leora Horn, Ben Solomon, & Jack West review whether there are specific factors that should make one second generation ALK inhibitor more ideal than other competing options for a specific patient with an ALK rearrangement.
Bronchioloalveolar carcinoma (BAC) is an unusual subtype of lung cancer; medical oncologist Dr. Jack West reviews the evidence on the best systemic therapy to treat advanced, multifocal BAC.
Dr. Jack West, medical oncologist/lung cancer specialist, describes special management considerations for indolent lung cancers that may not require treatment or are at risk for “over-treatment.”
Should older patients with lung cancer undergo surgery? What issues affect the probability of an elderly patients safely undergoing lung cancer...
Dr. Jed Gorden reviews the technique of pleurodesis to manage the complication of recurrent malignant pleural effusion (MPE). Transcript So we’re...
We couldn't do what we do without you, our volunteers! From sharing their own philanthropic efforts, helping at the ASCO booth, admin and...
GRACE and Living Yoga Therapy continue to provide more in our series on surviving with cancer. Our friend and partner, Raquel Jex Forsgren, founder of...
GRACE and Living Yoga Therapy continue to provide more in our series on surviving with cancer. Our friend and partner, Raquel Jex Forsgren, founder of...
GRACE and Living Yoga Therapy continue to provide more in our series on surviving with cancer. Our friend and partner, Raquel Jex Forsgren, founder of...
Drs. Nasser Hanna and Melissa Johnson discuss new trial evidence for the use of adjuvant Erlotinib for early-stage lung cancer.
[powerpress]
Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.
[powerpress]
The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.
[powerpress]
Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.
[powerpress]
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
[powerpress]
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.
[powerpress]
"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).
[powerpress]
One of the ongoing questions in managing EGFR mutation-positive advanced NSCLC has been whether it should be routine to do repeat biopsies to look for new findings after a patient has developed acquired resistance to an EGFR tyrosine kinase inhibitor (TKI). Here are a few posts in which the topic has been covered:
Lung cancer patients with high MET amplification appear to do well on Xalkori (crizotinib), a drug that is approved for ALK positive patients.
[powerpress]
Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.
[powerpress]
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.